drugset / Trial / NCT06718738
Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer
Phase 1
Recruiting
9 enrolled
Beijing Immunochina Medical Science & Technology Co., Ltd.
Peking University Cancer Hospital & Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This study, a single-center, open, single-dose clinical study, was designed to evaluate the safety and efficacy of IM96 CAR-T cells in treating patients with advanced colorectal cancer
Timeline
- Start
- 2024-12-15
- Primary completion
- 2025-08-15
- Completion
- 2026-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IM96 CAR-T Cells | Cell therapy | 1.2e+09 cells | — |
| Subject | IM96 CAR-T Cells | Cell therapy | 2e+09 cells | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |